Cardiovascular Adverse Events Associated With Bispecific T-Cell Engager Therapy - PubMed
4 hours ago
- #immunotherapy
- #cardiovascular events
- #T-cell engager therapy
- Cardiovascular adverse events (CVEs) associated with T-cell engager (TCE) therapy were studied in a dual-center retrospective analysis.
- Among 567 patients, the cumulative incidence of CVEs was 10.4%, with new left ventricular dysfunction (2.3%) and new-onset atrial fibrillation (2.1%) being the most common.
- Preexisting coronary artery disease and development of grade ≥2 cytokine-release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) were linked to increased CVE risk.
- CVEs during TCE therapy were significantly associated with higher all-cause mortality, independent of baseline factors or TCE agent.
- The study suggests intensified cardiovascular monitoring for high-risk groups, including patients with preexisting coronary artery disease or those developing high-grade CRS/ICANS.